Back

Asston Pharmaceuticals Ltd.

IPO Details · GMP · Subscription · Financials

✅ Listed BSE SME SME Live Chart
Issue Price
₹123
Per Share
GMP
NIL
Grey Market
Est. Listing
₹123
Expected Price
Min. Application
₹246,000
2 lots × 1000 shares
IPO Issue Details
Issue Price / Price Band₹123 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size1,000 Shares per Lot
Total Issue Size22,41,000 shares (aggregating up to ₹27.56 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital
Exchange / PlatformBSE SME
IPO TypeSME
Subscription OpenWed, 09 Jul 2025
Subscription CloseFri, 11 Jul 2025
Anchor AllotmentTue, 08 Jul 2025
Basis of AllotmentMon, 14 Jul 2025
Initiation of RefundsTue, 15 Jul 2025
Credit of Shares to DematTue, 15 Jul 2025
Listing DateWed, 16 Jul 2025
UPI Mandate Deadline2025-07-11
Application & Investment Details
Retail — Min (2 Lots)₹2,46,000 — 2000 shares
Retail — Max (13 Lots)₹1,599,000 (13 Lots)
HNI — Min (3 Lots)₹3,69,000 — 3000 shares
EPS (Pre-IPO)₹6.90
EPS (Post-IPO)₹9.32
P/E Ratio (Pre-IPO)17.83x
P/E Ratio (Post-IPO)13.2x
Net Offer to Public21,28,000 shares (aggregating up to ₹26.17 Cr)
Reserved for Market Maker1,13,000 shares (aggregating up to ₹1.39 Cr)
Pre-IPO Promoter Holding62,71,360 shares
Post-IPO Promoter Holding85,12,360 shares
About Asston Pharmaceuticals Ltd.

Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally.The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more.The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers.The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing.Products:Albendazole USP 400 mg: Albendazole USP 400 mg refers to a higher dosage of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication that is used to treat various parasitic worm infections.Diclofenac 100 mg: Diclofenac 100 mg refers to a specific dosage of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID).Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Acetaminophen) are two commonly used over-the-counter medications, often used to relieve pain and reduce fever.Ferrovit Syrup: To treat vitamin and mineral deficiencies.As of 3 July 2025, the company has 46 Permanent employees and 6 contractual employees in various departments.Competitive Strengths:Formulation ExpertiseExperienced PromotersWide range of ProductsStrategic LocationSkilled Workforce

Objects of the Issue

Asston Pharmaceuticals Ltd. proposes to utilise the net proceeds from the Issue for the following objects:

1
1 Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit
6.00
2
2 Funding the incremental working capital requirements of the Company
13.00
3
3 Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company
1.00
4
4 General Corporate Purposes
3.95
Shareholding & Lock-in
Pre-IPO Promoter Holding 62,71,360 shares
Post-IPO Promoter Holding 85,12,360 shares
Check AllotmentCheck Status →
Asston Pharmaceuticals Ltd. — Live Price LIVE
₹123.00
INR · BSE
Fetching live data…
VS Issue Price
OPEN
HIGH
LOW
MKT CAP
P/E
52W HIGH
52W LOW
VOLUME
DIVIDEND
DIV YIELD
Loading chart…
Chart Not Available
Asston Pharmaceuticals Ltd. is not yet listed on Yahoo Finance or has a different ticker symbol.
Try again after listing stabilises (2-3 trading days).
Issue ₹123.00 Live Price
Quick Facts
GMP Signal ⚪ No GMP
StatusListed
Issue Price₹123
GMPNIL
Est. Listing₹123
Lot Size1,000 shares
Min Amount₹246,000
Listing Date16 Jul 2025
Disclaimer: GMP is unofficial and unregulated. It does not guarantee actual listing price.
Listing Performance
Issue Price₹123
Listing Date16 Jul 2025
Listing Price
Listing Gain/Loss—%
52-Week High
52-Week Low
Issue Structure & Reservation
Category Shares Offered % Issue Amount (₹ Cr)* Subscription
Market Maker 113,000 ₹1.39 Cr
TOTAL 2,241,000 100.00% ₹27.56 Cr
* Based on ₹123.00 (upper price band)
Lot Size & Investment Details
Lot Size
1,000
Shares
Issue Price
₹123.00
Per Share
Min Investment
₹123,000
1 Lot
Category Lots Shares Amount (₹)
Retail (Min) 1 1,000 ₹123,000
Retail (Max) 13 13,000 ₹1,599,000
sNII (Min) 14 14,000 ₹1,722,000
bNII (Min) 68 68,000 ₹8,364,000
Company Financials — Restated Consolidated (Amount In Crore)
Particulars31 May 202531 Mar 202531 Mar 2024
Revenue from Operations 6.21 25.61 15.84
EBITDA 1.93 6.16 2.55
Profit After Tax (PAT) 1.32 4.33 1.36
Net Worth 12.04 10.72 6.39
Total Assets 31.83 28.12 20.26
Reserves & Surplus 5.77 4.45 5.61
Total Borrowings 7.83 7.26 6.82
Key Ratios & Valuation
Issue Price ₹123
Face Value ₹10 Per Share
P/BV 12.07
RoE 50.56%
RoCE 51.25%
RoNW 40.36%
PAT Margin (%) 17.27%
EBITDA Margin (%) 24.60%
Debt / Equity 0.68
Company Details
Company
Asston Pharmaceuticals Ltd.
Exchange
BSE SME
IPO Type
SME IPO
Issue Type
Bookbuilding IPO
Face Value
₹10 Per Share
Script Code
N/A
Address
4th Floor, Office No. A-431 Balaji Bhavan, Plot No 42A Sector-11 CBD Belapur, Navi Mumbai, Thane Navi Mumbai, Maharashtra, 400614
Book Running Lead Managers
Sobhagya Capital Options Pvt.Ltd.
Book Running Lead Manager (BRLM)